The page is the record's research on the issuer — no analyst, no rating, no view. # BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing BridgeBio Oncology Therapeutics, Inc. is listed on NASDAQ under ticker BBOT, with ISIN US1079241022. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). The security type is Corporate, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States — Delaware. The segment is not on the record. The issuer is listed, not halted. ## The disclosure read The record holds 70 filings across 32 filing days in the twelve months to 2026-11-08. The median gap between filing days is 5 days. The latest filing is dated 2026-11-05, 3 days before the record date, and is of type director_change. Filings by type are: directors_dealings 32, prospectus 11, regulatory_filing 10, director_change 5, results 8, agm_egm 2, corporate_news 2. On NASDAQ the median is 52 filings, a median cadence gap of 6.0 days, and a median latency of 5.0 days across 4359 issuers. In sector 2834 Pharmaceutical Preparations the median is 63.0 filings, a median cadence gap of 6.0 days, and a median latency of 4.0 days across 526 issuers. ## Auditor The auditor of record is not on the record (no dei:AuditorName tag on the latest annual report cover; foreign private issuers and older filings carry none). The auditor's location is not on the record. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted. ## Orderability The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the issuer's own investor-relations page, and the count is 0. ## Open research No openly published research notes were found, and the count is 0. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The issuer's years sealed are 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 7 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001869105.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NASDAQ/BBOT (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/BBOT (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/BBOT · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp